Pharmacopoeia reflects on permissible pharmaceutical impurities in parts per million limits
Journal Title: Journal of Drug Discovery and Therapeutics - Year 2015, Vol 3, Issue 5
Abstract
PAT (Process Analytical Technology) produces enormous amount of inorganic impurities during unit operation. Inorganic impurities are mostly ionic matters which are water soluble cations & anions. Cations are iron (Fe2+/Fe3+), arsenic (As3+/As5+), lead (Pb2+) and anions are chloride (Cl-), sulfate (SO42-). All heavy metal impurities are cumulative poison which has affinity to bind with lipid layer to produce health hazards. Pharmacopoeia says about permissible limit of each ion in parts per million (ppm) level which is acceptable by the living body with no harmful effect. This is checked by limit test which is quantitative or semi-quantitative analysis to identify the permissible impurity which is below the adverse effect. The test is generally performed by turbidity/opalescence comparison test, color comparison test and stain comparison test between test sample and standard sample. If the intensity of turbidity/colour/stain of test sample is equal to or less than standard sample then the sample passes the limit test, if the intensity of turbidity/color/stain of test sample is greater than standard sample then the sample fails to pass the limit test.
Authors and Affiliations
Neha A. Bhatt and Prof. Dr. Dhrubo Jyoti Sen| Department of Quality Assurance & Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Gujarat Technological University, Arvind Baug, Mehsana-384001, Gujarat, India
Keywords
Related Articles
- EP ID EP1626
- DOI -
- Views 2543
- Downloads 673
Docking and QSAR based screening of some naturally occurring diterpenes as inhibitors of angiotensin converting enzyme (ACE) against cardiovascular diseases
Many plants have been listed in the traditional systems of medicine and some of these are providing comprehensive relief to the people suffering from cardio-vascular diseases (CVD) and are recognized for their ability to...
DEVELOPMENT OF SUSTAINED RELEASE DOSAGE FORM OF GLICLAZIDE
The main aim of present work was to prepare solid dispersion of poorly water soluble drug Gliclazide to enhance its in-vitro dissolution rate and aqueous solubility of drug. Gliclazide is a second generation of hypoglyce...
SYNTHESIS, CHARACTERIZATION AND ANTIMICROBIAL SCREENING OF NOVEL SERIES OF BIS-IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
imidazo[1,2-a]pyridine. All the synthesized compounds have been characterized by using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported by mass spectroscopy. Purity of all the compounds has b...
LUBIPROSTONE: A NOVEL DRUG TO TREAT CONSTIPATION
Lubiprostone, a bicyclic fatty acid, is a novel drug of new class of agents called prostones. It is approved by US FDA for the treatment of chronic constipation and constipation associated irritable bowel syndrome (IBS-...
FORMULATION AND EVALUATION OF COLON TARGETED DELAYED RELEASE MICROSPHERIC CAPSULES OF ALBENDAZOLE
The aim of the present work was to prepare and evaluate the colon targeted delayed release microspheric capsules of albendazole. The preparation of albendazole microspheres by ionic gelation method avoids the usage of to...